KR20210095663A - Effervescent oral tablet in sealed container - Google Patents

Abstract

The components (A) ~ (C) containing, _{non-(H B) / (H A} ) of the mole number of the component (B) Component (A) of the mole number of the acid group of the acid group of component (B) is citric acid or 0.1-4.0 when it consists only of its salt or consists only of ascorbic acid or its salt, 0.05-5.5 when a component (B) consists of a combination of citric acid or its salt, and ascorbic acid or its salt, and also component (A) and ratio of the number of moles of the total molar amount component (C) of the acid group of _{(B) [(H a)} + (H B)] / (C) is expandable in the oral tablets containing, sealed container 0.7 ~ 1.35. (A) Tartaric acid or a salt thereof 0.1 to 22 mass% (B) Citric acid, ascorbic acid or a salt thereof (C) Carbonate 14 to 30 mass%

Description

Effervescent oral tablet in sealed container

The present invention relates to an effervescent oral tablet in a sealed container.

It is known that by the foaming of carbon dioxide gas, a salivation promoting effect, an enhancing effect of a component acting on the throat, and a good feeling of use by foaming in the mouth are obtained.

For example, Patent Document 1 discloses a candy with good productivity and storage properties, containing saccharides and a combination of an organic acid as a foaming component and a carbonate or hydrogen carbonate, and having a maltose content of 25% by weight or less in the saccharide. . In addition, Patent Document 2 discloses an expandable chewable tablet containing an oligosaccharide, a foaming agent component, and a neutralizing agent component and having good texture and stability.

Japanese Patent Laid-Open No. 2004-16073 Japanese Patent Laid-Open No. 2001-8666

The present invention, the following components (A) ~ (C) containing, _{non-(H B) / (H A} ) of the mole number of the component (B) Component (A) of the mole number of the acid group of the acid group is, component a ( 0.1 or more and 4.0 or less when B) consists only of citric acid or a salt thereof or only ascorbic acid or a salt thereof, and 0.05 or more and 5.5 or less when component (B) consists of a combination of citric acid or a salt thereof and ascorbic acid or a salt thereof, and , and components (a) and (B) the total molar amount component (C) contains the ratio of the number of moles _{[(H a) + (H} B)] / (C) is 0.7 or more 1.35 or less, sealed container of the acid groups To provide an effervescent oral tablet with

(A) At least one selected from tartaric acid and salts thereof 0.1 mass% or more and 22 mass% or less

(B) at least one selected from citric acid, ascorbic acid and salts thereof

(C) at least one selected from carbonates 14% by mass or more and 30% by mass or less

When a conventional effervescent oral preparation contains a high amount of carbonate or organic acid, which is an effervescent component, in order to enhance effervescence, a reaction between the carbonate and acid proceeds during storage, which causes the effervescent oral preparation to be placed in a sealed container. When sealed in the container, there was a problem in storage stability, such as the expansion of the container and the increase in hygroscopicity to change the appearance after opening. However, no attention has been paid to such a problem until now.

Accordingly, the present invention relates to an effervescent oral tablet contained in a sealed container which has a pleasant foaming feeling when taken with high foaming, and also has high storage stability, without expansion when the container is sealed or change in appearance due to moisture absorption after opening. .

As a result of intensive studies, the inventors of the present invention have combined a specific organic acid so that the molar ratio of acid groups is within a certain range, even when the content of carbonate is high in order to improve foamability, and the total moles of the number of moles of carbonate and acid groups of the organic acid in the agent It has been found that by formulating in a certain range, an effervescent oral tablet in a sealed container can be obtained which has an excellent rate of foaming in the mouth and good storage stability without expansion of the container or change in appearance after opening. .

The effervescent oral tablet contained in the sealed container of the present invention has an excellent foaming rate in the mouth, and there is no change in appearance due to expansion during container sealing or moisture absorption after opening, and is excellent in storage stability.

[Component (A): tartaric acid, its salt]

A component (A) is 1 or more types chosen from tartaric acid and its salt. When component (A) is a tartrate salt, an alkali metal salt is preferable as a salt, 1 or more types chosen from a sodium salt and potassium salt among these are preferable, Furthermore, a sodium salt is preferable.

The content of component (A) in the effervescent oral tablet is 0.1 mass% or more from the viewpoint of realizing an excellent foaming rate in the mouth, suppressing swelling, and suppressing moisture absorption after opening, preferably is 3 mass % or more, more preferably 5 mass % or more, still more preferably 7 mass % or more, and is 22 mass % or less from the viewpoint of suppressing expansion and moisture absorption after opening, preferably Preferably it is 20 mass % or less, More preferably, it is 18 mass % or less, More preferably, it is 15 mass % or less. And the content of component (A) in the effervescent oral tablet is 0.1 to 22 mass%, preferably 3 to 20 mass%, more preferably 5 to 18 mass%, still more preferably 7 to 15 mass%. % or less. In addition, content of a component (A) is an acid conversion amount.

The effervescent oral mole number (H _A) of the acid group of the component (A) in the tablet (m㏖ / 100 g) are perspective view, suppressing the expansion of the container to realize an excellent firing rate in the mouth, and From the viewpoint of suppressing moisture absorption after opening, preferably 2 mmol/100 g or more, more preferably 30 mmol/100 g or more, still more preferably 70 mmol/100 g or more, still more preferably 90 m mol / 100 g or more, and from the viewpoint of suppressing the expansion of the container, and from the viewpoint of suppressing moisture absorption after opening, preferably 310 mmol / 100 g or less, more preferably 270 mmol / 100 g or less, More preferably, it is 240 mmol/100g or less, More preferably, it is 200 mmol/100g or less. The number of moles of acid groups of the component (A) in the effervescent oral tablet is preferably 2 to 310 mmol/100 g, more preferably 30 to 270 mmol/100 g, and still more preferably 70 to It is 240 mmol/100g, More preferably, it is 90-200 mmol/100g.

In addition, the acidic radical in this invention points out the site|part in the structure which has a hydrogen atom which can ionize as a proton, For example, a carboxyl group and the hydroxyl group located at 3-position in ascorbic acid are mentioned. Moreover, when it has two or more acidic radicals in a compound, the value which multiplied the number of acidic radicals with respect to 1 mmol/100g of a compound is defined as the number of moles of an acidic radical. For example, since tartaric acid has two carboxyl groups in its structure, the number of acid groups is 2, the number of acid groups of ascorbic acid is 1, and the number of acid groups of citric acid is 3.

[Ingredient (B): citric acid, ascorbic acid, their salts]

A component (B) is 1 or more types chosen from citric acid, ascorbic acid, and those salts. When the component (B) is a citrate or ascorbate salt, from the viewpoint of realizing good taste at the time of taking, the salt is preferably an alkali metal salt, and among them, at least one selected from sodium salt and potassium salt is preferable, Furthermore, sodium salt is preferable. As the component (B), any of them can be used alone or in combination of two or more, from the viewpoint of realizing an excellent foaming rate in the mouth, suppressing the expansion of the container, and from the viewpoint of suppressing moisture absorption after opening , citric acid or a salt thereof, and ascorbic acid or a salt thereof are preferably used in combination.

The content of component (B) in the effervescent oral tablet is preferably 1 mass % or more, more preferably 2 mass % or more, still more preferably 4 mass % or more from the viewpoint of realizing an excellent foaming rate in the mouth. % or more, and from the viewpoint of suppressing the expansion of the container, and from the viewpoint of suppressing moisture absorption after opening, preferably 50 mass% or less, more preferably 45 mass% or less, still more preferably 40 mass% or less. . And content of the component (B) in an effervescent oral tablet becomes like this. Preferably it is 1-50 mass %, More preferably, it is 2-45 mass %, More preferably, it is 4-40 mass %. In addition, content of a component (B) is an acid conversion amount, and the following description is also described similarly.

_{In addition, the mole number (H B} ) (mmol/100 g) of the acid groups of the component (B) in the effervescent oral tablet is preferably 10 mmol/100 from the viewpoint of realizing an excellent foaming rate in the mouth. g or more, more preferably 20 mmol/100 g or more, still more preferably 25 mmol/100 g or more, and from the viewpoint of suppressing expansion of the container and suppressing moisture absorption after opening, preferably is 270 mmol/100 g or less, more preferably 260 mmol/100 g or less, and still more preferably 250 mmol/100 g or less. The number of moles of acid groups of the component (B) in the effervescent oral tablet is preferably 10 to 270 mmol/100 g, more preferably 20 to 260 mmol/100 g, still more preferably 25 to 250 It is mmol/100 g.

When the component (B) consists only of citric acid or a salt thereof, the content of the component (B) in the effervescent oral tablet is preferably 4 mass% or more, more preferably from the viewpoint of realizing an excellent foaming rate in the mouth. Preferably it is 5 mass % or more, More preferably, it is 7 mass % or more, From a viewpoint of suppressing expansion of a container, and a viewpoint of suppressing moisture absorption after opening, Preferably it is 15 mass % or less, More preferably, 12 It is mass % or less, More preferably, it is 10 mass % or less. The content of the component (B) in the effervescent oral tablet when the component (B) consists only of citric acid or a salt thereof is preferably 4 to 15 mass%, more preferably 5 to 12 mass%, still more preferably Preferably it is 5-10 mass %, More preferably, it is 7-10 mass %.

In addition, when the component (B) consists only of citric acid or a salt thereof, the number of moles (mmol/100 g) of the acid groups of the component (B) in the effervescent oral tablet is determined from the viewpoint of realizing an excellent foaming rate in the mouth. , preferably 40 mmol/100 g or more, more preferably 60 mmol/100 g or more, still more preferably 70 mmol/100 g or more, even more preferably 100 mmol/100 g or more, Moreover, from a viewpoint of suppressing the expansion of a container, and a viewpoint of suppressing moisture absorption after opening, Preferably it is 250 mmol/100g or less, More preferably, it is 240 mmol/100g or less, More preferably, it is 190 mmole. /100 g or less, and still more preferably 160 mmol/100 g or less. The number of moles of acid groups of the component (B) in the effervescent oral tablet when the component (B) consists only of citric acid or a salt thereof is preferably 40 to 250 mmol/100 g, more preferably 60 to 240 mmol/100g, More preferably, it is 70-190 mmol/100g, More preferably, it is 70-160 mmol/100g, Especially preferably, it is 100-160 mmol/100g.

Moreover, when the component (B) consists only of ascorbic acid or its salt, the content of the component (B) in the effervescent oral tablet is preferably 5 mass% or more from the viewpoint of realizing an excellent foaming rate in the mouth. , more preferably 10 mass% or more, still more preferably 12 mass% or more, and from the viewpoint of suppressing expansion of the container and suppressing moisture absorption after opening, preferably 40 mass% or less, more preferably Preferably it is 36 mass % or less, More preferably, it is 30 mass % or less, More preferably, it is 25 mass % or less. The content of the component (B) in the effervescent oral tablet when the component (B) consists only of ascorbic acid or a salt thereof is preferably 5 to 40 mass%, more preferably 10 to 36 mass%, further Preferably it is 10-30 mass %, More preferably, it is 12-25 mass %.

In addition, when the component (B) consists only of ascorbic acid or a salt thereof, the number of moles (mmol/100 g) of the acid groups of the component (B) in the effervescent oral tablet is from the viewpoint of realizing an excellent foaming rate in the mouth. in, preferably 25 mmol/100 g or more, more preferably 55 mmol/100 g or more, still more preferably 65 mmol/100 g or more, and from a viewpoint of suppressing expansion of the container, and unsealing From the viewpoint of suppressing moisture absorption afterward, preferably 230 mmol/100 g or less, more preferably 210 mmol/100 g or less, still more preferably 175 mmol/100 g or less, still more preferably 145 m ㏖/100 g. The number of moles of acid groups of the component (B) in the effervescent oral tablet when the component (B) consists only of ascorbic acid or a salt thereof is preferably 25 to 230 mmol/100 g, more preferably 55 to It is 210 mmol/100g, More preferably, it is 55-175 mmol/100g, More preferably, it is 65-145 mmol/100g.

Component (B) is citric acid or made or only a salt thereof, the sum of the molar amount of ascorbic acid or an acid group in this case composed only of the salt ingredient molar amount and composition of the acid group of (B) (A) [( H A) + (H B )] is, from the viewpoint of realizing an excellent foaming rate in the mouth, from the viewpoint of suppressing the expansion of the container, and from the viewpoint of suppressing moisture absorption after opening, preferably 130 mmol/100 g or more, more preferably 150 mmol/100 g or more, more preferably 170 mmol/100 g or more, and from the same viewpoint, preferably 350 mmol/100 g or less, more preferably 330 mmol/100 g or less, further Preferably it is 320 mmol/100g or less. Then, the component (B) is citric acid or made or only a salt thereof, ascorbic acid or the sum of the number of moles of the acid group of the component molar amount and composition of the acid group of (B) (A) in a case composed only of the salt [(H _A) + (H _B )], Preferably it is 130-350 mmol/100g, More preferably, it is 150-330 mmol/100g, More preferably, it is 170-320 mmol/100g.

When component (B) consists only of citric acid or a salt thereof, or consists only of ascorbic acid or a salt thereof, the ratio of the number of moles of acid groups of component (B) to the number of moles of acid groups of component (A) [(H _B )/(H) _A )] is 0.1 or more, preferably 0.2 or more, more preferably 0.4 or more, and is 4.0 or less, preferably 3.5 or less, more preferably 2.0 or less, still more preferably 1.6 or less. Then, the component (B) _{[(H B) / (H} A)] in the case where citric acid or made or only a salt thereof, containing only ascorbic acid or a salt thereof is 0.1 to 4.0, preferably from 0.1 to 3.5 , More preferably, it is 0.2-2.0, More preferably, it is 0.4-1.6.

When the component (B) consists of citric acid or a salt thereof and ascorbic acid or a salt thereof, the total content of the component (B) in the effervescent oral tablet is preferably from the viewpoint of realizing an excellent foaming rate in the mouth. is 1 mass % or more, more preferably 2 mass % or more, still more preferably 4 mass % or more, and from the viewpoint of suppressing expansion of the container and suppressing moisture absorption after opening, preferably 40 mass % % or less, more preferably 35 mass% or less, still more preferably 27 mass% or less. The content of the component (B) in the effervescent oral tablet when the component (B) consists of citric acid or a salt thereof and ascorbic acid or a salt thereof is preferably 1 to 40 mass%, more preferably 2 to 35 mass %, More preferably, it is 4-27 mass %.

When the component (B) consists of citric acid or a salt thereof and ascorbic acid or a salt thereof, the molar number of acid groups (mmol/100 g) of the component (B) in the effervescent oral tablet is an excellent foaming rate in the mouth. From the viewpoint of realizing the From a viewpoint and a viewpoint of suppressing moisture absorption after opening, Preferably it is 240 mmol/100g or less, More preferably, it is 230 mmol/100g or less, More preferably, it is 220 mmol/100g or less. And, when the component (B) consists of citric acid or a salt thereof and ascorbic acid or a salt thereof, the total number of moles of the acid groups of the component (B) in the effervescent oral tablet is preferably 30 to 240 mmol/100 g, More preferably, it is 40-230 mmol/100g, More preferably, it is 50-200 mmol/100g.

When component (B) consists of citric acid or its salt and ascorbic acid or its salt, the content mass ratio of citric acid or its salt to ascorbic acid or its salt (citric acid or its salt/ascorbic acid or its salt) is From a viewpoint of realizing an excellent foaming rate, a viewpoint of suppressing the expansion of a container, and a viewpoint of suppressing moisture absorption after opening, Preferably it is 0.05 or more, More preferably, it is 0.1 or more, and from the same viewpoint, Preferably it is 10 Hereinafter, more preferably, it is 8 or less. In the case where the component (B) consists of citric acid or a salt thereof and ascorbic acid or a salt thereof, the content mass ratio (citric acid or a salt thereof/ascorbic acid or a salt thereof) is preferably 0.05 to 10, more preferably 0.1 ∼ 8.

Further, component (B) is citric acid or a salt thereof and ascorbic acid, or, if made of a salt thereof, ascorbic acid or the number of moles of the acid salt _{(H b2) (m㏖ / 100} g) the number of moles of citric acid or a salt thereof for the _{The molar ratio [(H b1} )/(H _b2 )] of (H _b1 ) (mmol/100 g) is, from the viewpoint of realizing an excellent foaming rate in the mouth, from the viewpoint of suppressing the expansion of the container, and moisture absorption after opening From the viewpoint of suppressing , preferably 0.1 or more, more preferably 0.3 or more, and from the same viewpoint, preferably 30 or less, more preferably 25 or less. In the case where the component (B) consists of citric acid or a salt thereof and ascorbic acid or a salt thereof, the molar ratio [(H _b1 )/(H _b2 )] is preferably 0.1 to 30, more preferably 0.3 to 25 am.

Component (B) in the case composed of a citric acid or a salt thereof and ascorbic acid or a salt thereof, the sum of the number of moles of the component molar amount and composition of the acid group of (B) (A) acid _{[(H A) + (H} B)] is, from the viewpoint of realizing an excellent foaming rate in the mouth, from the viewpoint of suppressing the expansion of the container, and from the viewpoint of suppressing moisture absorption after opening, preferably 130 mmol/100 g or more, more preferably 150 mmol /100 g or more, more preferably 170 mmol/100 g or more, still more preferably 220 mmol/100 g, and from the same viewpoint, preferably 350 mmol/100 g or less, more preferably is 330 mmol/100 g or less, more preferably 320 mmol/100 g or less. Then, the component (B) is citric acid or a salt thereof and the sum of the number of moles of the case made of ascorbic acid and salts thereof specifically range from _{[(H A) + (H} B)] is preferably 130 ~ 350 m㏖ / 100 g, More preferably, it is 150-330 mmol/100g, More preferably, it is 170-320 mmol/100g, More preferably, it is 220-320 mmol/100g.

Component (B) is citric acid or a salt thereof and ascorbic acid, or, if made of a salt, the molar ratio for the acid group-the number of moles of the component (B) Component (A) of the mole number of the acid group of the _{[(H B) / (H} A) ] is 0.05 or more, preferably 0.1 or more, more preferably 0.2 or more, from a viewpoint of realizing an excellent foaming rate in the mouth, a viewpoint of suppressing the expansion of a container, and a viewpoint of suppressing moisture absorption after opening, More preferably, it is 0.25 or more, and from the same viewpoint, it is 5.5 or less, Preferably it is 4.5 or less, More preferably, it is 4.0 or less, More preferably, it is 3.0 or less. And when the component (B) consists of citric acid or a salt thereof and ascorbic acid or a salt thereof, the molar ratio [(H _B )/(HA _A )] is 0.05 to 5.5, preferably 0.1 to 4.5, More preferably, it is 0.2-4.0, More preferably, it is 0.25-3.0. In the effervescent oral tablet of the present invention, when citric acid or a salt thereof and ascorbic acid or a salt thereof are used in combination, the component (A) with the number of moles of acid groups of the component (B) exhibits the effect of the invention than when either one is used. ), the range of the molar ratio [(H _B )/(HA _A )] to the number of moles of acid groups can be expanded.

[Component (C): Carbonate]

A component (C) is 1 or more types chosen from carbonate. As carbonate, sodium carbonate, sodium hydrogencarbonate, potassium carbonate, potassium hydrogencarbonate, ammonium carbonate, sodium sesquicarbonate etc. are mentioned, for example. These can be used individually or in combination of 2 or more types. Especially, from a viewpoint of realizing the excellent foaming rate in a mouth, Preferably it is 1 or more types selected from sodium carbonate, sodium hydrogencarbonate, and potassium carbonate, More preferably, it is sodium hydrogencarbonate.

The content of component (C) in the effervescent oral tablet of the present invention is 14 mass % or more, preferably 15 mass % or more, more preferably 18 mass % from the viewpoint of realizing an excellent foaming rate in the mouth. % or more, and is 30 mass% or less, preferably 25 mass% or less, more preferably 22 mass% or less, from the viewpoint of suppressing the expansion of the container and suppressing moisture absorption after opening. The specific range of content of component (C) in the effervescent oral tablet of this invention is 14-30 mass %, Preferably it is 15-25 mass %, More preferably, it is 18-25 mass %, More preferably, It is 18-22 mass % or less. In addition, content of a component (C) is an acid conversion amount.

Further, the mole number (mmol/100 g) of component (C) in the effervescent oral tablet of the present invention is preferably 160 mmol/100 g or more from the viewpoint of realizing an excellent foaming rate in the mouth. , more preferably 175 mmol/100 g or more, still more preferably 210 mmol/100 g or more, and from the viewpoint of suppressing the expansion of the container, and from the viewpoint of suppressing moisture absorption after opening, preferably 360 It is mmol/100g or less, More preferably, it is 300 mmol/100g or less, More preferably, it is 265 mmol/100g or less. The number of moles (mmol/100 g) of component (C) in the effervescent oral tablet of the present invention is preferably 160 to 360 mmol/100 g, more preferably 175 to 300 mmol/100 g , More preferably, it is 210-300 mmol/100g, More preferably, it is 210-265 mmol/100g.

The molar ratio _{([(H A) + (} H B)] / (C)) for the number of moles of component (A) and the total molar amount components of the acid group of (B) (C) in the foamable oral tablets of the invention , from a viewpoint of realizing an excellent foaming rate in the mouth, from a viewpoint of suppressing the expansion of a container, and from a viewpoint of suppressing moisture absorption after opening, it is 0.7 or more, Preferably it is 0.78 or more, More preferably, it is 0.9 or more, and , from the same viewpoint, it is 1.35 or less, preferably 1.30 or less, more preferably 1.15 or less. In addition, the molar ratio _{([(H A) + (} H B)] / (C)) is 0.7 ~ 1.35, preferably 0.78 ~ 1.30, more preferably 0.78 ~ 1.15, more preferably 0.9 to 1.15 am.

Effervescent oral tablet of the present invention, in the range that does not impair the effects of the present invention other than the above components, sweeteners, vitamins, minerals, extracts, acidulants other than components (A) and (B), flavorings, coloring agents, preservatives, etc. may be appropriately contained. Content of an additive can be set suitably within the range which does not impair the objective of this invention.

[Carrier] The effervescent oral tablet of the present invention may contain an acceptable carrier as necessary. For example, excipients (eg, monosaccharides such as glucose, galactose, and fructose, disaccharides such as sucrose, lactose, maltose, trehalose, palatinose, maltitol, xylitol, erythritol, sorbitol, reduced palatinose) sugar alcohols such as); binders (eg, hydroxypropylmethylcellulose, hydroxypropylcellulose, gelatin, pregelatinized starch, polyvinylpyrrolidone, polyvinyl alcohol, pullulan, methylcellulose, hydrogenated oil, etc.); disintegrating agents (eg, carmellose, carmellose calcium, croscarmellose sodium, crospopidone, corn starch, low-substituted hydroxypropyl cellulose, etc.); lubricants (eg, calcium stearate, magnesium stearate, sucrose fatty acid ester, sodium stearyl fumarate, talc, silicon dioxide, etc.); copulating agents (eg, stevia, menthol, aspartame, etc.); and carriers such as oligosaccharides, agar, crystalline cellulose, powdered cellulose, light anhydrous silicic acid, calcium hydrogen phosphate, extenders, surfactants, dispersants, buffers, and diluents. In addition, content of a support|carrier can be set suitably within the range which does not impair the objective of this invention.

Among them, it is preferable that the effervescent oral tablet of the present invention contains a sugar alcohol from the viewpoint of suppressing the expansion of the container and from the viewpoint of suppressing moisture absorption after opening. The sugar alcohol may be either an anhydride or a hydrate.

The content of the sugar alcohol in the effervescent oral tablet is preferably 10 mass% or more, more preferably 20 mass% or more, further preferably from the viewpoint of suppressing the expansion of the container and from the viewpoint of suppressing moisture absorption after opening. is 30 mass% or more, and from the viewpoint of realizing an excellent foaming rate in the mouth, preferably 85 mass% or less, more preferably 80 mass% or less, still more preferably 65 mass% or less. The specific range of content of the sugar alcohol in an effervescent oral tablet becomes like this. Preferably it is 10-85 mass %, More preferably, it is 20-80 mass %, More preferably, it is 30-65 mass %.

HPLC can be used for quantification of sugar alcohol. For example, it can be analyzed by differential refraction detection using an amino-based column (“Food Fiber Basics and Applications”, Supervised by: Japanese Dietary Fiber Society, Edited by: Japanese Dietary Fiber Society Editorial Board et al., Author: Seiichiro Aoki) , Publisher: Daiichi Publishing Co., Ltd., Release Date: October 2008).

As the sealed container for sealing the effervescent tablet in the present invention, an air impermeable container, particularly a carbon dioxide impermeable container is preferable. It is possible to use a packaging container deposited with a metal, glass, or the like. The carbon dioxide impermeability as used herein means that the carbon dioxide permeability is 50 cc/m 2 ·day·atm (ASTD-1434) or less. By sealing the container using such a raw material by sealing, etc., it can seal so that carbon dioxide gas does not leak.

In the form of the effervescent oral tablet of the present invention, carbon dioxide gas in the presence of moisture such as saliva in the mouth from the viewpoint of realizing an excellent foaming rate in the mouth, from the viewpoint of suppressing swelling, and from the viewpoint of suppressing moisture absorption after opening Chewable tablets, which are in the form of generating , are preferred.

[Manufacturing method]

In order to manufacture the effervescent oral tablet of the present invention, in addition to components (A) to (C), additives added as needed may be mixed, and the mixture may be used as a raw material powder and directly compressed and molded by a tableting machine. , a dry granulation method, a wet granulation method, etc. may be used for granulation, and then the granulated product may be compressed and molded by a tableting molding machine. As the tableting molding machine, a conventionally used tableting machine such as a rotary tableting machine or a single-shot tableting machine can be used. The compression molding pressure at the time of tableting is preferably about 10 to 30 MPa from the viewpoint of maintaining the hardness of the molded product. Moreover, it is preferable that tablet hardness is a hardness which can withstand conveyance, storage, etc., and, specifically, about 10 N-200N is preferable.

And by encapsulating the thus obtained effervescent oral tablet in the sealed container, the effervescent oral tablet contained in the sealed container of the present invention can be obtained.

Preferred embodiments of the effervescent oral tablet of the present invention include the following components (A) to ( C) contained, the molar ratio for the acid group-the number of moles of the component (B component (a of the mole number of the acid _{group)) [(H B) /} (H a)] is 0.1 or more than 4.0, and also the component (a) and the ( the B) (molar ratio (for the number of moles of C) [(H _a) + (H _B)] component of the total molar amount / (C) of the acid group) 0.7 1.35 or less, the expandable oral tablets contained in the sealed container can

(A) At least one selected from tartaric acid and salts thereof 0.1 mass% or more and 22 mass% or less

(B) at least one selected from citric acid and its salts

(C) at least one selected from carbonates 14% by mass or more and 30% by mass or less

As another preferred aspect of the effervescent oral tablet of the present invention, the following component (A) , (B1), (B2) and (C) to be contained, and the molar ratio for the acid group-the number of moles of the component (B) component (a) of the mole number of the acid group of the _{[(H B) / (H} a)] is 0.05 or more 5.5 or less, and also the component (a) and (B) molar ratio _{([(H a) + (} H B)] / (C)) for the number of moles of the total molar amount component (C) of the acid group is 0.7 or more 1.35 or less and an effervescent oral tablet contained in a sealed container in which the content ratio [(B1)/(B2)] of the component (B1) to the component (B2) is 0.05 or more and 4 or less.

(A) At least one selected from tartaric acid and salts thereof 0.1 mass% or more and 22 mass% or less

(B1) at least one selected from citric acid and its salts

(B2) at least one selected from ascorbic acid and its salts

(C) at least one selected from carbonates 14% by mass or more and 30% by mass or less

Regarding the above-mentioned embodiment, the preferable aspect of this invention is further disclosed below.

<1> following components (A) ~ (C) containing, _{non-(H B) / (H A} ) of the mole number of the component (B) Component (A) of the mole number of the acid group of the acid group is, components for (B ) is 0.1 or more and 4.0 or less when it consists only of citric acid or a salt thereof, or only ascorbic acid or a salt thereof, and 0.05 or more and 5.5 or less when the component (B) consists of a combination of citric acid or a salt thereof and ascorbic acid or a salt thereof, in addition, component (a) and (B) a ratio of the number of moles of the component of the total molar amount (C) of the acid _{[(H a) + (H} B)] / (C) is contained in not more than, a sealed container above 0.7 1.35 Effervescent oral tablet.

(A) At least one selected from tartaric acid and salts thereof 0.1 mass% or more and 22 mass% or less

(B) at least one selected from citric acid, ascorbic acid and salts thereof

(C) at least one selected from carbonates 14% by mass or more and 30% by mass or less

<2> Content of component (A) is an acid conversion amount, Preferably it is 3 mass % or more, More preferably, it is 5 mass % or more, More preferably, it is 7 mass % or more, More preferably, it is 20 mass % or more. % or less, more preferably 18 mass% or less, still more preferably 15 mass% or less, the effervescent oral tablet contained in the sealed container according to <1>.

<3> molar number (H _A) of the acid group of the component (A) (m㏖ / 100 g ) is, preferably 2 m㏖ / 100 g or more, more preferably 30 m㏖ / 100 g or more, more preferably is 70 mmol/100 g or more, more preferably 90 mmol/100 g or more, and preferably 310 mmol/100 g or less, more preferably 270 mmol/100 g or less, still more preferably is 240 mmol/100 g or less, more preferably 200 mmol/100 g or less, an effervescent oral tablet contained in the sealed container according to <1> or <2>.

<4> Content of component (B) becomes like this. Preferably it is 1 mass % or more, More preferably, it is 2 mass % or more, More preferably, it is 4 mass % or more, More preferably, it is 50 mass % or less, More preferably The effervescent oral tablet contained in the sealed container according to any one of <1> to <3>, which is preferably 45 mass% or less, more preferably 40 mass% or less.

<5> the molar number _{(H B) (m㏖ / 100} g) of the acid group of the component (B), preferably 10 m㏖ / 100 g or more, and more preferably 20 m㏖ / 100 g or more, more preferably is 25 mmol/100 g or more, preferably 270 mmol/100 g or less, more preferably 260 mmol/100 g or less, still more preferably 250 mmol/100 g or less, <1> - An effervescent oral tablet contained in the sealed container in any one of <4>.

<6> The component (B) consists only of citric acid or a salt thereof, and the content of the component (B) is preferably 4 mass% or more, more preferably 5 mass% or more, still more preferably 7 mass% or more, Further, preferably 15 mass% or less, more preferably 12 mass% or less, still more preferably 10 mass% or less, the effervescent oral tablet contained in the sealed container according to any one of <1> to <5>. .

<7> The component (B) consists only of citric acid or a salt thereof, and the number of moles (mmol/100 g) of the acid groups of the component (B) is preferably 40 mmol/100 g or more, more preferably 60 m mol/100g or more, more preferably 70 mmol/100g or more, still more preferably 100 mmol/100g or more, and preferably 250 mmol/100g or less, more preferably 240 mmol/100 g or less, more preferably 190 mmol/100 g or less, even more preferably 160 mmol/100 g or less, contained in the sealed container according to any one of <1> to <6>. Effervescent oral tablet.

<8> The component (B) consists only of ascorbic acid or a salt thereof, and the content of the component (B) is preferably 5 mass% or more, more preferably 10 mass% or more, still more preferably 12 mass% or more. Any one of <1> to <5>, which is preferably 40 mass% or less, more preferably 36 mass% or less, still more preferably 30 mass% or less, even more preferably 25 mass% or less An effervescent oral tablet in a sealed container according to claim.

<9> The component (B) consists only of ascorbic acid or a salt thereof, and the number of moles (mmol/100 g) of the acid groups of the component (B) is preferably 25 mmol/100 g or more, more preferably 55 mmol/100g or more, More preferably 65 mmol/100g or more, Preferably it is 230 mmol/100g or less, More preferably, it is 210 mmol/100g or less, More preferably, it is 175 mmol/100g or less. An effervescent oral tablet contained in the sealed container according to any one of <1> to <5> and <8>, wherein the content is less than or equal to mmol/100 g, more preferably 145 mmol/100 g.

<10> The component (B) is citric acid or made or only a salt thereof, ascorbic acid, or as composed of only a salt thereof, component (B) number of moles in total (H _A) of the number of moles and component acid group of (A) of the acid group-+ ( H _B ) is preferably 130 mmol/100 g or more, more preferably 150 mmol/100 g or more, still more preferably 170 mmol/100 g or more, and preferably 350 mmol/ An effervescent oral tablet contained in the sealed container according to any one of <1> to <9>, which is 100 g or less, more preferably 330 mmol/100 g or less, and still more preferably 320 mmol/100 g or less.

<11> In which component (B) consists only of citric acid or a salt thereof, or consists only of ascorbic acid or a salt thereof, the ratio (H _B )/ of (H _a) is preferably 0.2 or more, more preferably 0.4 or more, and, preferably 3.5 or less, more preferably 2.0 or less, more preferably 1.6 or less, <1> to <10> An effervescent oral tablet contained in the sealed container of any one of claims.

<12> Preferably, the effervescent oral tablet contained in the sealed container according to any one of <1> to <5>, wherein the component (B) consists of citric acid or a salt thereof and ascorbic acid or a salt thereof.

<13> Total content of component (B) becomes like this. Preferably it is 1 mass % or more, More preferably, it is 2 mass % or more, More preferably, it is 4 mass % or more, More preferably, it is 40 mass % or less. The effervescent oral tablet contained in the sealed container as described in <12>, Preferably it is 35 mass % or less, More preferably, it is 27 mass % or less.

<14> The number of moles (mmol/100 g) of acid groups of the component (B) is preferably 30 mmol/100 g or more, more preferably 40 mmol/100 g or more, still more preferably 50 mmol /100 g or more, preferably 240 mmol/100 g or less, more preferably 230 mmol/100 g or less, still more preferably 220 mmol/100 g or less, <12> or <13> An effervescent oral tablet in a sealed container as described in.

<15> The content mass ratio of citric acid or its salt to ascorbic acid or its salt (citric acid or its salt/ascorbic acid or its salt) is preferably 0.05 or more, more preferably 0.1 or more, and more preferably 10 Hereinafter, the effervescent oral tablet contained in the sealed container according to any one of <12> to <14>, more preferably 8 or less.

<16> ascorbic acid, or the ratio (H _b1) of the number of moles of the salt of acid group _{(H b2) (m㏖ / 100} g) the number of moles of citric acid or a salt thereof to _{(H b1) (m㏖ / 100} g) / ( H _b2 ) is preferably 0.1 or more, more preferably 0.3 or more, and preferably 30 or less, more preferably 25 or less, in the sealed container according to any one of <12> to <15>. Effervescent oral tablet containing.

<17> The component (B) Total _(A H) of the molar number of the acid group of the component group of the number of moles of (A) + (H _B) is preferably 130 m㏖ / 100 g or more, more preferably 150 m mol/100 g or more, more preferably 170 mmol/100 g or more, still more preferably 220 mmol/100 g, and preferably 350 mmol/100 g or less, more preferably 330 m An effervescent oral tablet contained in the sealed container according to any one of <12> to <16>, which is mol/100 g or less, more preferably 320 mmol/100 g or less.

<18> The component ratio _{(H B) / (H A} ) of the group number of moles of the component (B) (A) of the mole number of the acid group, preferably 0.1 or more, more preferably 0.2 or more, and more preferably is 0.25 or more, preferably 4.5 or less, more preferably 4.0 or less, still more preferably 3.0 or less.

<19> Component (C) is preferably at least one selected from the group consisting of sodium carbonate, sodium hydrogen carbonate, potassium carbonate, potassium hydrogen carbonate, ammonium carbonate and sodium sesquicarbonate, more preferably sodium carbonate and sodium hydrogen carbonate and at least one selected from the group consisting of potassium carbonate, more preferably sodium hydrogencarbonate. The effervescent oral tablet contained in the sealed container according to any one of <1> to <18>.

<20> Content of component (C) becomes like this. Preferably it is 15 mass % or more, More preferably, it is 18 mass % or more, Preferably it is 25 mass % or less, More preferably, it is 22 mass % or less, <1 An effervescent oral tablet contained in the sealed container according to any one of > to <19>.

<21> The number of moles (mmol/100 g) of the component (C) is more preferably 175 mmol/100 g or more, still more preferably 210 mmol/100 g or more, and preferably 360 m Effervescent oral cavity contained in the sealed container according to any one of <1> to <20>, which is less than or equal to mol/100 g, more preferably less than or equal to 300 mmol/100 g, still more preferably less than or equal to 265 mmol/100 g. refine.

<22> component (A) and the ratio _{[(H A) + (H} B)] of the number of moles of component (C) of the total molar amount / (C) of the group (B), preferably 0.78 or more, more The effervescent oral tablet contained in the sealed container according to any one of <1> to <21>, which is preferably 0.9 or more, preferably 1.30 or less, more preferably 1.15 or less.

<23> The effervescent oral tablet contained in the sealed container according to any one of <1> to <22>, which preferably further contains a sugar alcohol.

<24> Content of sugar alcohol becomes like this. Preferably it is 10 mass % or more, More preferably, it is 20 mass % or more, More preferably, it is 30 mass % or more, More preferably, it is 85 mass % or less, More preferably The effervescent oral tablet contained in the sealed container as described in <23> which is 80 mass % or less, More preferably, it is 65 mass % or less.

<25> The effervescent oral tablet contained in the sealed container according to any one of <1> to <24>, which is preferably a chewable tablet.

<26> the following components (A) ~ (C) contains the component (B) ratio (H _B) to the molar number of the component (A) of the number of moles acid group of the acid group / (H _A) is 0.1 or more than 4.0 a , and components (a) and (B) the total molar amount component (C) contains the ratio of the number of moles _{[(H a) + (H} B)] / (C) is 0.7 or more 1.35 or less, sealed container of the acid groups Effervescent oral tablet.

(A) At least one selected from tartaric acid and salts thereof 0.1 mass% or more and 22 mass% or less

(B) at least one selected from citric acid and its salts

(C) at least one selected from carbonates 14% by mass or more and 30% by mass or less

<27> It contains the following components (A), (B1), (B2) and (C), and the ratio (H _B )/( and H _a) is more than 5.5, not more than 0.05, and components (a) and (B) ratio _{[(H a) + (H} B)] of the number of moles of component (C) of the total molar amount / (C) of the acid group is An effervescent oral tablet contained in a sealed container which is 0.7 or more and 1.35 or less, and the content ratio (B1)/(B2) of component (B1) and component (B2) is 0.05 or more and 4 or less.

(A) At least one selected from tartaric acid and salts thereof 0.1 mass% or more and 22 mass% or less

(B1) at least one selected from citric acid and its salts

(B2) at least one selected from ascorbic acid and its salts

(C) at least one selected from carbonates 14% by mass or more and 30% by mass or less

Example

Effervescent oral tablets of the compositions shown in Tables 1 to 5 were prepared, and the foamability and stability were evaluated according to the following method.

[Effervescent property (foaming speed)]

Invert the 100 ml measuring cylinder filled with water in the thermostat. Put 2 tablets each in the measuring cylinder and dissolve. At that time, the amount of bubbles collected in the measuring cylinder per minute was taken as the foaming amount, and was used as an index of foamability. It shows that it is excellent in foamability, so that a numerical value is high.

[Stability (change in appearance after opening)]

Each tablet was put in a 25 degreeC 75% thermostat, the change in appearance after 24 hours was confirmed, and the following reference|standard evaluated.

4: Little change

3: I see very little change

2: I see a little change

1: The tablet is deformed by foaming

[Individual packaging expansion volume]

Each tablet was put in an aluminum pill (60 mm x 60 mm), and after sealing, it preserve|saved for 1 week in a 60 degreeC thermostat. The volume of pilos before and after storage was measured by the Archimedes method, and the amount of change in volume of pilos before and after storage was calculated. It shows that expansion is suppressed, so that a numerical value is low.

[Foaming feeling]

Three panelists evaluated the foaming feeling when one tablet was put in the mouth according to the following criteria. The evaluation result was decided by three people's consultation. The criteria were divided into 4 stages, and Example 5, which felt a very strong feeling of effervescence at the time of taking, was set as 4 of the evaluation criteria, and Comparative Example 15, which did not feel very comfortable effervescent feeling at the time of taking, was evaluated as 1.

4: I feel the pleasant foam feeling quite strongly

3: I feel a strong feeling of comfortable foaming

2: I feel a little pleasant foaming feeling

1: Pleasant foaming feeling is not felt very much

[Raw material]

Maltitol: Amalti MR-50 (Mitsubishi Corporation Foodtech Co., Ltd.)

Tartaric acid: L-tartaric acid (Fuso Chemical Industry Co., Ltd.)

Citric acid: fuso citrate (anhydrous) (Fuso Chemical Industry Co., Ltd.)

Ascorbic Acid: Vitamin C TypeS (Fuso Chemical Industry Co., Ltd.)

sodium bicarbonate: sodium bicarbonate (Sikcheom C) (Toso Co., Ltd.)

Calcium Stearate: Calcium Stearate (Taihei Chemical Co., Ltd.)

Powdered Cellulose: KC-Flock W-400G (Nippon Paper Co., Ltd.)

Silicon dioxide: Carplex FPS-500 (EVONIK)

Aspartame: PALSWEETDIET (Ajinomoto Co., Ltd.)

Claims (4)

_{The following components (A) to (C) are contained, and the ratio (H B} )/(HA ) of the number of moles of the acid group of the component (B) to the number of moles of the acid group of the component ( _A ) is, the component (B) is citric acid or a salt thereof alone, or 0.1 or more and 4.0 or less when it consists only of ascorbic acid or a salt thereof, 0.05 or more and 5.5 or less when the component (B) consists of a combination of citric acid or a salt thereof and ascorbic acid or a salt thereof, and a component ( a) and (B) a ratio of the number of moles of the total molar amount component (C) of [(H _a) + (H _B)] / (C) is 0.7 or more 1.35 or less, for effervescent oral tablets in a sealed container of the acid group of the .
(A) At least one selected from tartaric acid and salts thereof 0.1 mass% or more and 22 mass% or less
(B) at least one selected from citric acid, ascorbic acid and salts thereof
(C) at least one selected from carbonates 14% by mass or more and 30% by mass or less The method of claim 1,
An effervescent oral tablet in a sealed container, wherein the component (B) consists of citric acid or a salt thereof and ascorbic acid or a salt thereof. 3. The method according to claim 1 or 2,
An effervescent oral tablet in a sealed container that is a chewable tablet. 4. The method according to any one of claims 1 to 3,
Effervescent tablets in a sealed container, further containing a sugar alcohol.